Showing 3071-3080 of 3315 results for "".
- Secondhand Smoke May Damage Children’s Eyeshttps://modernod.com/news/secondhand-smoke-may-damage-childrens-eyes/2477043/Secondhand smoke may damage children’s eyes and possibly lead to problems with sight later in life, new findings suggest. In a study of Chinese children, increasing exposure to secondhand smoke was associated with choroidal th
- More Evidence Links Common Bladder Drug to Retinal Damagehttps://modernod.com/news/more-evidence-links-common-bladder-drug-to-retinal-damage/2477044/Pentosan polysulfate sodium (PPS), used widely for interstitial cystitis, may lead to retinal damage, according to a new study that adds weight to this previously suggested link, as reported by Reuters. Interstitial cystitis causes
- Johnson & Johnson Vision Releases Data From Study of Acuvue Oasys With Transitions Light Intelligent Technologyhttps://modernod.com/news/johnson-johnson-vision-releases-data-from-study-of-acuvue-oasys-with-transitions-light-intelligent-technology/2477034/Johnson & Johnson Vision announced new data from a study of its Acuvue Oasys with Transitions Light Intelligent Technology, which found the benefits of these first-of-its-kind light adaptive contact lens were deemed highly valued and useful by people who had never w
- ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10https://modernod.com/news/proqr-receives-rare-pediatric-disease-designation-from-fda-for-sepofarsen-for-the-treatment-of-lca10/2477018/ProQR Therapeutics announced that it received Rare Pediatric Disease (RPD) designation from the FDA for sepofarsen for the treatment of Leber’s congenital amaurosis 10 (LCA10), the most common cause of blindness due to genetic disease in children. Sepofarsen (QR-110) is a first-in-class in
- Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at AAOhttps://modernod.com/news/aura-biosciences-announces-updated-phase-1b-2-clinical-data-for-au-011-presented-at-aao/2477015/Aura Biosciences announced the presentation of updated clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of
- New Approach to Slowing Nearsightedness in Children Shows Promisehttps://modernod.com/news/new-approach-to-slowing-nearsightedness-in-children-shows-promise/2477006/Combining two different treatment methods to slow the progression of myopia may deliver better results than either can achieve on their own. A new, 2-year study shows that treating children with eye drops and contact lenses was 28 percent to 38 percent more effective in slowing myopia. The resear
- Optos Unveils Silverstone Combined Ultra-Widefield Retinal Imaging Device and UWF-Guided Swept Source OCThttps://modernod.com/news/optos-unveils-silverstone-combined-ultra-widefield-retinal-imaging-device-and-uwf-guided-swept-source-oct/2476998/Optos has announced the launch of Silverstone at the American Academy of Ophthalmology in San Francisco. Silverstone is the first-of-its-kind, combining world-leading ultra-widefield retinal imaging with integrated, image-guided, swept source OCT. Silverstone produces a 200° single capture
- Mynosys Secures $25 Million Investment; Names Rob Thornhill as CEOhttps://modernod.com/news/mynosys-secures-25-million-investment-names-rob-thornhill-as-ceo/2476976/Mynosys Cellular Devices, manufacturer of the Zepto cataract surgery device, announced it finalized a $25 million financing round, led by Decheng Capital, and named veteran ophthalmology industry executive Rob Thornhill as Chief Executive Officer. This financing provides capital to fuel U.
- ProQR Announces Positive Topline Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patientshttps://modernod.com/news/proqr-announces-positive-topline-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10-patients/2476975/ProQR Therapeutics announced positive topline results from the PQ-110-001 study, a phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported toda
- Ex-Shire CEO Flemming Ornskov Emerges as Galderma CEO after $10B Nestlé Spinouthttps://modernod.com/news/ex-shire-ceo-flemming-ornskov-emerges-as-galderma-ceo-after-10b-nestle-spinout/2476966/As Takeda folds in Shire, two of the Irish rare disease specialist’s former top leaders have found themselves a new home at Nestlé skin health spinoff Galderma, according to a report in FiercePharma. Flemming Ornskov, Shire’s most recent CEO before the Takeda buyout, has